Targeted Therapies in Triple-Negative Breast Cancer

被引：56

作者：

Marme, Frederik ^{[1
,2
]}

Schneeweiss, Andreas ^{[1
,2
]}

机构：

[1] Heidelberg Univ, Univ Frauenklin, D-69115 Heidelberg, Germany

[2] Heidelberg Univ, Natl Ctr Tumour Dis, D-69115 Heidelberg, Germany

来源：

BREAST CARE | 2015年 / 10卷 / 03期

关键词：

Triple-negative breast cancer; Subtypes; PARP inhibitors; Immune-checkpoint inhibitors; Targeted therapy; Bevacizumab; RANDOMIZED PHASE-II; BEVACIZUMAB-CONTAINING THERAPY; 1ST-LINE TREATMENT; NEOADJUVANT CHEMOTHERAPY; OPEN-LABEL; PLUS PACLITAXEL; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; TRIAL; COMBINATION;

D O I：

10.1159/000433622

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) is a heterogeneous disease comprised of several biologically distinct subtypes. However, treatment is currently mainly relying on chemotherapy as there are no targeted therapies specifically approved for TNBC. Despite initial responses to chemotherapy, resistance frequently and rapidly develops and metastatic TNBC has a poor prognosis. New targeted approaches are, therefore, urgently needed. Currently, bevacizumab, a monoclonal anti-vascular endothelial growth factor (VEGF)-A antibody, is the only targeted agent with an approval for the therapy of metastatic breast cancer, but does not provide a specific benefit in the TNBC subtype. This review discusses the current clinical developments in targeted approaches for TNBC, including anti-angiogenic therapies, epidermal growth factor receptor (EGFR)-targeted therapies, poly(ADP-ribose) polymerase (PARP) inhibitors and platinum salts, as well as novel strategies using immune-checkpoint inhibitors, which have recently demonstrated first promising results. Strategies focusing on specific subtypes of TNBC like anti-androgenic therapies for the luminal androgen receptor subtype (LAR) and others are also discussed.

引用

页码：159 / 166

页数：8

共 72 条

[1] Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array [J].

Andre, Fabrice ;

Job, Bastien ;

Dessen, Philippe ;

Tordai, Attila ;

Michiels, Stefan ;

Liedtke, Cornelia ;

Richon, Catherine ;

Yan, Kai ;

Wang, Bailang ;

Vassal, Gilles ;

Delaloge, Suzette ;

Hortobagyi, Gabriel N. ;

Symmans, W. Fraser ;

Lazar, Vladimir ;

Pusztai, Lajos .

CLINICAL CANCER RESEARCH, 2009, 15 (02) :441-451

[2] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].

Audeh, M. William ;

Carmichael, James ;

Penson, Richard T. ;

Friedlander, Michael ;

Powell, Bethan ;

Bell-McGuinn, Katherine M. ;

Scott, Clare ;

Weitzel, Jeffrey N. ;

Oaknin, Ana ;

Loman, Niklas ;

Lu, Karen ;

Schmutzler, Rita K. ;

Matulonis, Ursula ;

Wickens, Mark ;

Tutt, Andrew .

LANCET, 2010, 376 (9737) :245-251

[3] Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets [J].

Balko, Justin M. ;

Giltnane, Jennifer M. ;

Wang, Kai ;

Schwarz, Luis J. ;

Young, Christian D. ;

Cook, Rebecca S. ;

Owens, Phillip ;

Sanders, Melinda E. ;

Kuba, Maria G. ;

Sanchez, Violeta ;

Kurupi, Richard ;

Moore, Preston D. ;

Pinto, Joseph A. ;

Doimi, Franco D. ;

Gomez, Henry ;

Horiuchi, Dai ;

Goga, Andrei ;

Lehmann, Brian D. ;

Bauer, Joshua A. ;

Pietenpol, Jennifer A. ;

Ross, Jeffrey S. ;

Palmer, Gary A. ;

Yelensky, Roman ;

Cronin, Maureen ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Arteaga, Carlos L. .

CANCER DISCOVERY, 2014, 4 (02) :232-245

[4] Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance [J].

Balko, Justin M. ;

Cook, Rebecca S. ;

Vaught, David B. ;

Kuba, Maria G. ;

Miller, Todd W. ;

Bhola, Neil E. ;

Sanders, Melinda E. ;

Granja-Ingram, Nara M. ;

Smith, J. Joshua ;

Meszoely, Ingrid M. ;

Salter, Janine ;

Dowsett, Mitch ;

Stemke-Hale, Katherine ;

Gonzalez-Angulo, Ana M. ;

Mills, Gordon B. ;

Pinto, Joseph A. ;

Gomez, Henry L. ;

Arteaga, Carlos L. .

NATURE MEDICINE, 2012, 18 (07) :1052-+

[5] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer [J].

Barrios, Carlos H. ;

Liu, Mei-Ching ;

Lee, Soo Chin ;

Vanlemmens, Laurence ;

Ferrero, Jean-Marc ;

Tabei, Toshio ;

Pivot, Xavier ;

Iwata, Hiroji ;

Aogi, Kenjiro ;

Lugo-Quintana, Roberto ;

Harbeck, Nadia ;

Brickman, Marla J. ;

Zhang, Ke ;

Kern, Kenneth A. ;

Martin, Miguel .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) :121-131

[6] Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer [J].

Baselga, Jose ;

Gomez, Patricia ;

Greil, Richard ;

Braga, Sofia ;

Climent, Miguel A. ;

Wardley, Andrew M. ;

Kaufman, Bella ;

Stemmer, Salomon M. ;

Pego, Antonio ;

Chan, Arlene ;

Goeminne, Jean-Charles ;

Graas, Marie-Pascale ;

Kennedy, M. John ;

Ciruelos Gil, Eva Maria ;

Schneeweiss, Andreas ;

Zubel, Angela ;

Groos, Jutta ;

Melezinkova, Helena ;

Awada, Ahmad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) :2586-+

[7] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].

Bauer, Katrina R. ;

Brown, Monica ;

Cress, Rosemary D. ;

Parise, Carol A. ;

Caggiano, Vincent .

CANCER, 2007, 109 (09) :1721-1728

[8] Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer [J].

Bear, Harry D. ;

Tang, Gong ;

Rastogi, Priya ;

Geyer, Charles E., Jr. ;

Robidoux, Andre ;

Atkins, James N. ;

Baez-Diaz, Luis ;

Brufsky, Adam M. ;

Mehta, Rita S. ;

Fehrenbacher, Louis ;

Young, James A. ;

Senecal, Francis M. ;

Gaur, Rakesh ;

Margolese, Richard G. ;

Adams, Paul T. ;

Gross, Howard M. ;

Costantino, Joseph P. ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Wolmark, Norman .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04) :310-320

[9] First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study [J].

Bergh, Jonas ;

Bondarenko, Igor M. ;

Lichinitser, Mikhail R. ;

Liljegren, Annelie ;

Greil, Richard ;

Voytko, Nataliya L. ;

Makhson, Anatoly N. ;

Cortes, Javier ;

Lortholary, Alain ;

Bischoff, Joachim ;

Chan, Arlene ;

Delaloge, Suzette ;

Huang, Xin ;

Kern, Kenneth A. ;

Giorgetti, Carla .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :921-929

[10] Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer [J].

Bianchi, Giulia ;

Loibl, Sibylle ;

Zamagni, Claudio ;

Salvagni, Stefania ;

Raab, Guenter ;

Siena, Salvatore ;

Laferriere, Nicole ;

Pena, Carol ;

Lathia, Chetan ;

Bergamini, Loredana ;

Gianni, Luca .

ANTI-CANCER DRUGS, 2009, 20 (07) :616-624

← 1 2 3 4 5 6 7 8 →